(S)-2-phenylvaline | 136032-94-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-phenylvaline
• 英文别名: (2S)-2-azaniumyl-3-methyl-2-phenylbutanoate
• CAS: 136032-94-5
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: XAWIYXBFKANEFM-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (1R,2R,5S,9R)-5-Isopropyl-2,10,10-trimethyl-5-phenyl-3-oxa-6-aza-tricyclo[7.1.1.0^2,7]undec-6-en-4-one 在 盐酸 、 methyloxirane 作用下， 生成 (S)-2-phenylvaline
  参考文献：
  名称：

  氟苯三羰基铬配合物与α-氨基酯席夫碱阴离子的反应；α-芳基氨基酸的对映选择性合成

  摘要：

  我们在这里报告了通过将α-氨基酯加到氟苯三羰基铬络合物中来方便地合成α-取代的芳基氨基酸的方法。通过使用L-丙氨酸，亮氨酸和缬氨酸甲酯的席夫碱和（1R，2R，5R）-2-羟基pinan-3-one的席夫碱对氟苯配合物进行对映选择性取代，制备了光学纯的α-芳基氨基酸。

  DOI：

  10.1016/s0040-4020(01)86468-1

文献信息

• Enantioselective Synthesis of α-Quaternary Amino Acids by Alkylation of Deprotonated α-Aminonitriles
  作者：Isabelle Netz、Murat Kucukdisli、Till Opatz

  DOI：10.1021/acs.joc.5b00868

  日期：2015.7.2

  A series of α-quaternary arylglycines were prepared in high optical purity (up to 98% ee) by α-alkylation of deprotonated α-aminonitriles derived by the Strecker reaction from (4S,5S)-5-amino-2,2-dimethyl-4-phenyl-1,3-dioxane. The procedure includes only chromatographic purification of the final products and is devoid of chromatography or crystallization operations on intermediates to raise the optical

  通过由（4 S，5 S）-5-氨基-2,2的Strecker反应衍生的去质子化的α-氨基腈的α-烷基化反应制备了一系列光学纯度高（高达ee达98％ee）的α-季芳基甘氨酸。 -二甲基-4-苯基-1,3-二恶烷。该方法仅包括最终产物的色谱纯化，并且没有对中间体进行色谱或结晶操作以提高光学纯度。
• Highly homogeneous molecular markers for electrophoresis
  申请人：Invitrogen Corporation

  公开号：US20040014082A1

  公开（公告）日：2004-01-22

  The invention relates to marker molecules for identifying physical properties of molecular species separated by the use of electrophoretic systems. The invention further relates to methods for preparing and using marker molecules.

  这项发明涉及用于识别电泳系统分离的分子物种的物理性质的标记分子。该发明还涉及制备和使用标记分子的方法。
• PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF
  申请人：Cai Sui Xiong

  公开号：US20080300191A1

  公开（公告）日：2008-12-04

  Disclosed are protease inhibitors for coronaviruses and SARS-CoV, or picornaviruses, and the use of these protease inhibitors for preventing, reducing, ameliorating and treating a disease or condition caused by coronaviruses and SARS-CoV, or picornaviruses. Also disclosed are methods of reducing or preventing the spread of coronavirus, or picornaviruses, and preventing or reducing the replication of coronavirus, or picornaviruses, with the compounds of the present invention

  本申请公开了用于冠状病毒和SARS-CoV，或小RNA病毒的蛋白酶抑制剂，以及利用这些蛋白酶抑制剂预防、减少、改善和治疗由冠状病毒和SARS-CoV，或小RNA病毒引起的疾病或症状的用途。还公开了使用本发明的化合物减少或预防冠状病毒，或小RNA病毒的传播，并预防或减少冠状病毒，或小RNA病毒的复制的方法。
• [EN] BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS<br/>[FR] COMPOSÉS DIACYLHYDRAZINE CONTENANT DU BORE
  申请人：INTREXON CORP

  公开号：WO2016044390A1

  公开（公告）日：2016-03-24

  The present disclosure provides boron-containing diacylhydrazines having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供具有式（I）的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物，其中A、R4和R5如规范中所述。本公开还提供了含硼二酰肼化合物在蜕皮激素受体基础上的诱导基因表达系统的用途。因此，本公开适用于基因治疗、疾病治疗、大规模蛋白质和抗体生产、基于细胞的筛选分析、功能基因组学、蛋白质组学、代谢组学和调节转基因生物的特征等应用中，其中对基因表达水平的控制是可取的。
• Boron-Containing Diacylhydrazines
  申请人：Intrexon Corporation

  公开号：US20150322092A1

  公开（公告）日：2015-11-12

  The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供具有I式的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物，其中R1、R2、R3、R4和R5的定义如规范中所述。本公开还提供了使用含硼二酰肼化合物的ecdysone受体基础的诱导基因表达系统。因此，本公开适用于基因治疗、疾病治疗、大规模生产蛋白质和抗体、基于细胞的筛选测定、功能基因组学、蛋白质组学、代谢组学和调控转基因生物的特征等应用，其中需要控制基因表达水平。